La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Amneal Pharmaceuticals Croissance future

Future contrôle des critères 1/6

Amneal Pharmaceuticals devrait augmenter ses bénéfices et son chiffre d'affaires de 139.5% et de 5.7% par an respectivement. Le BPA devrait croître de de 143.7% par an. Le rendement des capitaux propres devrait être 104.3% dans 3 ans.

Informations clés

139.5%

Taux de croissance des bénéfices

143.7%

Taux de croissance du BPA

Pharmaceuticals croissance des bénéfices	23.6%
Taux de croissance des recettes	5.7%
Rendement futur des capitaux propres	104.3%
Couverture par les analystes	Low
Dernière mise à jour	12 Aug 2024

Mises à jour récentes de la croissance future

Recent updates

Amneal Pharmaceuticals: Maintaining Momentum Is Key To Success

Jul 10

Revenues Working Against Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Share Price

Apr 15

Does Amneal Pharmaceuticals (NASDAQ:AMRX) Have A Healthy Balance Sheet?

Mar 19

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Stock Catapults 46% Though Its Price And Business Still Lag The Industry

Dec 28

These 4 Measures Indicate That Amneal Pharmaceuticals (NYSE:AMRX) Is Using Debt Extensively

Apr 18

Amneal Pharmaceuticals: Risk Still Persists

Jan 23

Amneal Pharma reaffirms 2022 guidance

Jan 10

Amneal joins hands with Orion to commercialize generic products in Europe and more countries

Jan 04

Here's Why Amneal Pharmaceuticals (NYSE:AMRX) Is Weighed Down By Its Debt Load

Dec 20

Amneal Pharmaceuticals large shareholder TPG cuts stake

Dec 14

FDA accepts Amneal Pharmaceuticals NDA for Parkinson's drug IPX203

Nov 11

Amneal Pharmaceuticals Q3 2022 Earnings Preview

Nov 03

Amneal Pharmaceuticals: A Small 'Thumbs Up'

Oct 28

Amneal Pharmaceuticals (NYSE:AMRX) Has A Somewhat Strained Balance Sheet

Sep 01

Amneal Pharma submits NDA for novel formulation of Parkinson's disease treatment

Aug 31

Amneal Pharmaceuticals Q2 2022 Earnings Preview

Aug 04

Prévisions de croissance des bénéfices et des revenus

NasdaqGS:AMRX - Estimations futures des analystes et données financières antérieures (USD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2026	3,031	N/A	409	365	2
12/31/2025	2,845	20	333	358	3
12/31/2024	2,749	-72	264	204	3
6/30/2024	2,598	-175	176	252	N/A
3/31/2024	2,495	-169	124	201	N/A
12/31/2023	2,394	-84	276	346	N/A
9/30/2023	2,386	10	137	186	N/A
6/30/2023	2,312	-2	114	199	N/A
3/31/2023	2,272	-135	-5	84	N/A
12/31/2022	2,212	-130	-25	65	N/A
9/30/2022	2,139	-132	53	152	N/A
6/30/2022	2,122	-134	80	140	N/A
3/31/2022	2,098	2	161	214	N/A
12/31/2021	2,094	11	189	242	N/A
9/30/2021	2,067	14	219	285	N/A
6/30/2021	2,058	9	176	247	N/A
3/31/2021	1,987	-17	408	478	N/A
12/31/2020	1,993	91	313	379	N/A
9/30/2020	1,880	62	183	222	N/A
6/30/2020	1,739	-194	283	317	N/A
3/31/2020	1,679	-199	71	159	N/A
12/31/2019	1,626	-362	-96	2	N/A
9/30/2019	1,727	-339	200	312	N/A
6/30/2019	1,825	-67	97	234	N/A
3/31/2019	1,834	-69	19	115	N/A
12/31/2018	1,663	-21	153	250	N/A
9/30/2018	1,459	155	-46	56	N/A
6/30/2018	1,237	149	-32	67	N/A
3/31/2018	1,083	168	N/A	192	N/A
12/31/2017	1,034	168	N/A	234	N/A
9/30/2017	1,039	54	N/A	205	N/A
12/31/2016	1,018	207	N/A	115	N/A
12/31/2015	866	169	N/A	105	N/A
12/31/2014	786	177	N/A	112	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: AMRX devrait rester non rentable au cours des 3 prochaines années.

Bénéfices vs marché: AMRX devrait rester non rentable au cours des 3 prochaines années.

Croissance élevée des bénéfices: AMRX devrait rester non rentable au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de AMRX ( 5.7% par an) devrait croître plus lentement que le marché de US ( 8.8% par an).

Croissance élevée des revenus: Le chiffre d'affaires de AMRX ( 5.7% par an) devrait croître plus lentement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Le retour sur capitaux propres de AMRX devrait être très élevé dans 3 ans ( 104.3 %).

Amneal Pharmaceuticals Croissance future

Future contrôle des critères 1/6

Informations clés

Mises à jour récentes de la croissance future

Amneal Pharmaceuticals, Inc. Raises Earnings Guidance for the Full Year 2024

Price target increased by 13% to US$8.25

Price target increased by 7.3% to US$7.31

Consensus EPS estimates fall by 17%

Amneal Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2024

Amneal Pharmaceuticals, Inc. Revises Earnings Guidance for the Year Ending December 31, 2023

Recent updates

Amneal Pharmaceuticals, Inc. Receives U.S. FDA Approval for Propofol Injectable Emulsion Single Dose Vials

Insider recently sold US$775k worth of stock

Insider notifies of intention to sell stock

Second quarter 2024 earnings released: EPS: US$0.019 (vs US$0.078 in 2Q 2023)

Amneal Pharmaceuticals, Inc. Raises Earnings Guidance for the Full Year 2024

Amneal Receives U.S. FDA Approval for IPX203 for Treatment of Parkinson’s Disease to Be Launched as CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules

Amneal Pharmaceuticals, Inc. Receives U.S. FDA Approval for Potassium Phosphates Injection IV Bags

Amneal Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 09, 2024

Amneal Pharmaceuticals: Maintaining Momentum Is Key To Success

Amneal Pharmaceuticals, Inc. Launches FOCINVEZ, the First Ready-to-Use Version of Fosaprepitant

Amneal Pharmaceuticals, Inc. Expands Biosimilars Portfolio to Eight Products with Addition of Omalizumab Biosimilar

Amneal Pharmaceuticals, Inc. Expands Broad Injectables Portfolio to over 40 Products with the Addition of Six New Therapies

Independent Director recently sold US$256k worth of stock

Independent Director notifies of intention to sell stock

Price target increased by 13% to US$8.25

New major risk - Negative shareholders equity

First quarter 2024 earnings released: US$0.30 loss per share (vs US$0.046 loss in 1Q 2023)

Amneal Announces U.S. FDA Approval of Over-The-Counter Naloxone Hydrochloride Nasal Spray for Emergency Treatment of an Opioid Overdose

Amneal Pharmaceuticals Announces Launch of Pemetrexed Injection, 100mg/10 Mg/10 Mg/50 Mg/Ll (NDA)

Revenues Working Against Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Share Price

Amneal Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 03, 2024

Amneal Pharmaceuticals, Inc., Annual General Meeting, May 02, 2024

Price target increased by 7.3% to US$7.31

Does Amneal Pharmaceuticals (NASDAQ:AMRX) Have A Healthy Balance Sheet?

Insider exercised options and sold US$332k worth of stock

Full year 2023 earnings: EPS misses analyst expectations

Consensus EPS estimates fall by 17%

Amneal Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2024

Amneal Pharmaceuticals, Inc. to Report Q4, 2023 Results on Mar 01, 2024

Amneal Pharmaceuticals, Inc. Announces the Approval and Launch of Fluorometholone Ophthalmic Suspension

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Stock Catapults 46% Though Its Price And Business Still Lag The Industry

Amneal Pharmaceuticals: By Most Measures, A Fundamentally Undervalued Company

Is Amneal Pharmaceuticals (NYSE:AMRX) Using Too Much Debt?

New major risk - Financial position

Amneal Pharmaceuticals, Inc. Revises Earnings Guidance for the Year Ending December 31, 2023

Amneal Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Amneal Pharmaceuticals: A High-Wire Act Between Growth And Debt

Amneal Pharmaceuticals, Inc. Receives U.S. Fda Approval for Calcium Gluconate Injection

Amneal Pharmaceuticals, Inc. Publishes Phase 3 Study Results Comparing Ipx203 to Immediate-Release Carbidopa/Levodopa for Parkinson's Disease

Is Amneal Pharmaceuticals (NYSE:AMRX) Using Too Much Debt?

Price target increased by 50% to US$5.25

Amneal Pharmaceuticals, Inc. Raises Revenue Guidance for the Full Year 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Amneal Pharmaceuticals, Inc. Submits Abbreviated New Drug Applications to U.S. FDA for Three Key Complex Generics

Amneal Pharmaceuticals Could Have An Upbeat Q2

Amneal Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 04, 2023

Amneal Launches Authorized Generic for Xyrem® (Sodium Oxybate) and Receives FDA Approval for Five Complex Generics in the Second Quarter

Amneal Receives 505(B)(2) Nda Approval from FDA for PEMRYDI RTU, A Ready-To-Use Oncology Injectable

Consensus EPS estimates fall by 25%

Amneal Pharmaceuticals, Inc. Launches Third Biosimilar with FYLNETRA™? (pegfilgrastim-pbbk) in the United States

Price target decreased by 18% to US$3.50

Amneal Pharmaceuticals, Inc. Reaffirms Earnings Guidance for the Year 2023

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

These 4 Measures Indicate That Amneal Pharmaceuticals (NYSE:AMRX) Is Using Debt Extensively

Price target decreased by 18% to US$4.20

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Amneal Pharmaceuticals, Inc. to Report Q4, 2022 Results on Mar 02, 2023

Amneal Pharmaceuticals: Risk Still Persists

Amneal Pharma reaffirms 2022 guidance

Amneal joins hands with Orion to commercialize generic products in Europe and more countries

Insufficient new directors

Amneal Pharmaceuticals, Inc. Announces 26 Generic New Product Launches in 2022 and First Injection Large Volume Bag Approval

Here's Why Amneal Pharmaceuticals (NYSE:AMRX) Is Weighed Down By Its Debt Load

Amneal Pharmaceuticals large shareholder TPG cuts stake

Amneal Launches Second Biosimilar with RELEUKO® (filgrastim-ayow) in the United States

Price target decreased to US$5.10

Amneal Pharmaceuticals, Inc. Announces U.S. FDA Filing Acceptance of New Drug Application for IPX203 for the Treatment of Parkinson’s Disease

FDA accepts Amneal Pharmaceuticals NDA for Parkinson's drug IPX203

Third quarter 2022 earnings: EPS and revenues miss analyst expectations